Keyphrases
Randomized Controlled Trial
100%
Chronic Obstructive Pulmonary Disease
100%
Morphine
100%
Acute Dyspnea
100%
Respiratory Adverse Effects
100%
Dyspnea
50%
Logistic Regression Analysis
16%
Clinically Significant
16%
Placebo
16%
Randomized Double-blind
16%
Placebo-controlled
16%
Effective Treatment
16%
Intervention Studies
16%
Regression Analysis
16%
Outcome Assessment
16%
Follow-up Examination
16%
Economic Evaluation
16%
Cost-effectiveness
16%
Control Intervention
16%
Societal Perspective
16%
Health-related Quality of Life
16%
Lung Function
16%
6-minute Walk Test (6MWT)
16%
Pulmonary Rehabilitation
16%
Exercise Capacity
16%
Dyspnea Score
16%
Single Center
16%
Advanced Chronic Obstructive Pulmonary Disease
16%
Clinical Consequences
16%
Carer Perspectives
16%
Cost Diary
16%
Clinical Practice Guidelines
16%
Undertreated
16%
Phone Calls
16%
Regression Logistic
16%
Oral Sustained Release
16%
Chronic Obstructive Pulmonary Disease Assessment Test
16%
Home Visits
16%
Arterial Blood Gasses
16%
Medicine and Dentistry
Dyspnea
100%
Chronic Obstructive Pulmonary Disease
100%
Randomized Controlled Trial
100%
Adverse Event
100%
Morphine
100%
Placebo
33%
Logistic Regression Analysis
16%
Health Care Cost
16%
Exercise
16%
Pulmonary Rehabilitation
16%
Rehabilitation Engineering
16%
Quality of Life
16%
Cost-Effectiveness Analysis
16%
Outcome Assessment
16%
Disease Assessment
16%
Intervention Study
16%
Six Minute Walk Test
16%
Weakness
16%
Sustained Drug Release
16%
Arterial Blood
16%
Lung
16%
INIS
diseases
100%
patients
100%
refractories
100%
morphine
100%
assessments
50%
interventions
50%
cost
33%
regression analysis
33%
lungs
16%
control
16%
symptoms
16%
comparative evaluations
16%
blood
16%
quality of life
16%
evaluation
16%
guidelines
16%
economics
16%
capacity
16%
exercise
16%
Nursing and Health Professions
Dyspnea
100%
Obstructive Lung Disease
100%
Adverse Event
100%
Morphine
100%
Placebo
33%
Logistic Regression Analysis
16%
Rehabilitation Engineering
16%
Pulmonary Rehabilitation
16%
Quality of Life
16%
Outcome Assessment
16%
Practice Guideline
16%
Disease Assessment
16%
Cost Effectiveness Analysis
16%
Six Minute Walk Test
16%
Weakness
16%
Economic Evaluation
16%
House Call
16%
Sustained Drug Release
16%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Dyspnea
100%
Adverse Event
100%
Chronic Obstructive Lung Disease
100%
Morphine
100%
Placebo
33%
Intervention Study
16%
Weakness
16%
Sustained Release
16%